CA2205112C - Method and composition for treating mammalian diseases caused by inflammatory response - Google Patents

Method and composition for treating mammalian diseases caused by inflammatory response Download PDF

Info

Publication number
CA2205112C
CA2205112C CA002205112A CA2205112A CA2205112C CA 2205112 C CA2205112 C CA 2205112C CA 002205112 A CA002205112 A CA 002205112A CA 2205112 A CA2205112 A CA 2205112A CA 2205112 C CA2205112 C CA 2205112C
Authority
CA
Canada
Prior art keywords
pyruvate
respiratory disease
inflammatory mediator
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002205112A
Other languages
English (en)
French (fr)
Other versions
CA2205112A1 (en
Inventor
Stanley E. Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellular Sciences Inc
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of CA2205112A1 publication Critical patent/CA2205112A1/en
Application granted granted Critical
Publication of CA2205112C publication Critical patent/CA2205112C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002205112A 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response Expired - Lifetime CA2205112C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US396295P 1995-09-19 1995-09-19
US60/003,962 1995-09-19
PCT/US1996/014304 WO1997010818A1 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response

Publications (2)

Publication Number Publication Date
CA2205112A1 CA2205112A1 (en) 1997-03-27
CA2205112C true CA2205112C (en) 2008-11-18

Family

ID=21708422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205112A Expired - Lifetime CA2205112C (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response

Country Status (10)

Country Link
EP (1) EP0804181A4 (xx)
JP (1) JP4459303B2 (xx)
AU (1) AU719332B2 (xx)
CA (1) CA2205112C (xx)
IL (1) IL119225A (xx)
MX (1) MX9703653A (xx)
NZ (1) NZ306832A (xx)
TW (1) TW434012B (xx)
WO (1) WO1997010818A1 (xx)
ZA (1) ZA967833B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373611C (en) * 1999-05-14 2009-06-23 Cellular Sciences, Inc. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
JP2004528307A (ja) * 2001-03-15 2004-09-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法
US6623723B2 (en) * 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
JP2020524144A (ja) 2017-06-16 2020-08-13 ヴァンダービルト ユニヴァーシティ 微生物性炎症を処置するための方法および組成物
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation
KR20220097972A (ko) * 2019-11-14 2022-07-08 메르크 파텐트 게엠베하 세포 배양 배지

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1857M (fr) * 1962-03-08 1963-06-10 Roussel Uclaf Nouveau médicament notamment pour le traitement des maladies d'origine virale.
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4521375A (en) * 1982-11-23 1985-06-04 Coopervision, Inc. Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof
DE3302694A1 (de) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München Mundpflegemittel
WO1986000227A1 (en) * 1984-06-22 1986-01-16 Veech Richard L Electrolyte solutions and in vivo use thereof
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
JPS63135370A (ja) * 1986-11-26 1988-06-07 Grelan Pharmaceut Co Ltd 抗アレルギ−剤
IN168530B (xx) * 1987-11-06 1991-04-20 Lyphomed Inc
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
JP2794021B2 (ja) * 1988-11-02 1998-09-03 エーザイ株式会社 アゼラスチン或いはその塩類含有経皮適用製剤
EP0477345A1 (en) * 1990-03-30 1992-04-01 Amgen Inc. Respiratory burst suppression factor
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
WO1993016690A1 (en) * 1992-02-25 1993-09-02 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
JP3236658B2 (ja) * 1992-04-27 2001-12-10 花王株式会社 気管支拡張剤
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof

Also Published As

Publication number Publication date
EP0804181A1 (en) 1997-11-05
ZA967833B (en) 1997-06-02
AU6915996A (en) 1997-04-09
WO1997010818A1 (en) 1997-03-27
AU719332B2 (en) 2000-05-04
IL119225A0 (en) 1996-12-05
NZ306832A (en) 2001-04-27
EP0804181A4 (en) 2005-02-02
JPH10509463A (ja) 1998-09-14
IL119225A (en) 2000-09-28
TW434012B (en) 2001-05-16
MX9703653A (es) 1998-07-31
CA2205112A1 (en) 1997-03-27
JP4459303B2 (ja) 2010-04-28

Similar Documents

Publication Publication Date Title
US5798388A (en) Method and composition for treating mammalian diseases caused by inflammatory response
AU2006213755B2 (en) Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
EP0792163B1 (en) Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
CA2457983C (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
JP3506701B2 (ja) 創傷治癒組成物，その調製方法と使用
AU2002329762A1 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
CA2205112C (en) Method and composition for treating mammalian diseases caused by inflammatory response
AU1328501A (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
US7122578B2 (en) Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
AU4275793A (en) Cytoprotective compositions containing pyruvate and antioxidants
JP2011190274A (ja) 炎症反応により生ずる哺乳動物の鼻および副鼻洞の病気を処置する方法および組成物
CZ20021559A3 (cs) Použití oxidu dusnatého pro výrobu léku k léčení konstrikce dýchacích cest
AU674131C (en) Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
EP0753309A2 (en) Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160906